Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Refametinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 known ✓ | Q02750 | 20/20 | 1.00 |
| ▸ | MAP2K2 known ✓ | P36507 | 6/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 1/20 | 1.00 |
| ▸ | PRKAG1 | P54619 | 1/20 | 1.00 |
| ▸ | ADCK1 | Q86TW2 | 1/20 | 1.00 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Refametinib SCHEMBL345334 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL29385439 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL345333 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL29360059 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL29358040 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL346872 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL10314890 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL29368551 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL16127640 | 0.94 | MAP2K1 (0.89) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL3691191 | 0.94 | MAP2K1 (0.88) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023044386-A1 | COMPOSITION FOR TREATING, PREVENTING, OR AMELIORATING MELANOMA AND METHOD THEREOF | THOMAS JEFFERSON UNIVERSITY (US) | 2023-03-23 | — | — | WO | claimed |
| WO-2025090966-A1 | MEK INHIBITORS, ALONE OR IN COMBINATION WITH CDK4/5 INHIBITORS, FOR USE IN TREATING CANCER | VEVO THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| EP-4504777-A1 | COMBINATION OF A GREMLIN-1 ANTAGONIST WITH AN INHIBITOR OF RAS-RAF-MEK-ERK SIGNALLING | UCB Biopharma SRL (BE) | 2025-02-12 | — | — | EP | disclosed |
| CN-118973580-A | Combination therapy comprising SOS1 inhibitor and MEK inhibitor | 米拉蒂治疗股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024171957-A1 | TRANSPLANTATION OF PITUITARY HORMONE-PRODUCING CELLS | 国立大学法人東海国立大学機構 | 2024-08-22 | — | — | WO | disclosed |
| EP-4410962-A1 | CELL AGGREGATE INCLUDING PITUITARY HORMONE-PRODUCING CELLS AND METHOD FOR PRODUCING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2024-08-07 | — | — | EP | disclosed |
| CN-118318033-A | Cell aggregate comprising pituitary hormone-producing cells and method for producing the same | 住友制药株式会社 | 2024-07-09 | — | — | CN | disclosed |
| CN-118043447-A | Method for preparing cell population containing pituitary tissue and cell population | 住友化学株式会社 | 2024-05-14 | — | — | CN | disclosed |
| EP-4346826-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117615762-A | Combination therapy | 米拉蒂治疗股份有限公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-4157448-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| WO-2023044386-A1 | COMPOSITION FOR TREATING, PREVENTING, OR AMELIORATING MELANOMA AND METHOD THEREOF | THOMAS JEFFERSON UNIVERSITY (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023008462-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | 東レ株式会社 | 2023-02-02 | — | — | WO | disclosed |
| WO-2023277135-A1 | METHOD FOR PRODUCING CELLS CONSTITUTING NASAL EPITHELIUM, AND CELL POPULATION INCLUDING CELLS CONSTITUTING NASAL EPITHELIUM OR PROGENITOR CELLS THEREOF | 住友化学株式会社 | 2023-01-05 | — | — | WO | disclosed |
| WO-2022251193-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022195551-A1 | BIOMARKERS FOR CANCER AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022165142-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2022-08-04 | — | — | WO | disclosed |
| WO-2022159763-A1 | SARS-COV-2 THERAPEUTICS | MODEL MEDICINES, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-20220096590-A1 | NOVEL-ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS | ATRIVA THERAPEUTICS GMBH (DE) | 2022-03-31 | — | — | US | disclosed |
| CN-114127266-A | Selective differentiation regulating method for musculoskeletal system stem cells | 雪拉托兹治疗株式会社 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096590-A1 | NOVEL-ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS | MAPK1, MAP2K1, MAP2K6 | MAP2K1 2/4885MAP2K2 11/4885CHEK1 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.